Pregnancy in a woman with secondary osteoporosis. A case report

Abstract

BACKGROUND: Glucocorticoid-induced osteoporosis is one of the most serious complications of prolonged (more than three months) systemic glucocorticoid therapy. Rapid bone loss occurs in the first months of treatment, which is a significant risk factor, especially during pregnancy and lactation. When taking systemic glucocorticoid therapy in a daily dose of 5 mg or more (in prednisone equivalent), the relative risk of vertebral fractures increases by 2.9 times.

RESULTS: This article examines a clinical case of pregnancy and childbirth of 32-year-old woman diagnosed with secondary complicated osteoporosis during treatment with systemic glucocorticosteroids, who has a history of spine compression fractures during lactation after a previous pregnancy. Vitamin D deficiency was diagnosed and corrected during this pregnancy, which minimized the risk of fractures. A baby was delivered through the birth canal. Bisphosphonate therapy was started six months after birth. No new fractures were diagnosed within two years of observation.

CONCLUSIONS: The approach to the management, diagnosis and delivery of pregnant patients with secondary osteoporosis treated long-term with glucocorticosteroids should be multidisciplinary. It is imperative to prescribe vitamin D and calcium preparations throughout pregnancy and lactation.

Keywords

clinical case / secondary osteoporosis / bone diseases / glucocorticosteroids / pregnancy

References

[1] Han JT, Lee SY. A comparison of vital capacity between normal weight and underweight women in their 20s in South Korea. J Phys Ther Sci. 2012;24(5):379–381. DOI: 10.1589/jpts.24.379

[2] Han J.T., Lee S.Y. A comparison of vital capacity between normal weight and underweight women in their 20s in South Korea//J. Phys. Ther. Sci. 2012. Vol. 24. No. 5. P. 379–381. DOI: 10.1589/jpts.24.379

[3] Cavkaytar S, Seval MM, Atak Z, et al. Effect of reproductive history, lactation, first pregnancy age and dietary habits on bone mineral density in natural postmenopausal women. Aging Clin Exp Res. 2015;27(5):689–694. DOI: 10.1007/s40520-015-0333-4

[4] Cavkaytar S., Seval M.M., Atak Z. et al. Effect of reproductive history, lactation, first pregnancy age and dietary habits on bone mineral density in natural postmenopausal women//Aging. Clin. Exp. Res. 2015. Vol. 27. No. 5. P. 689–694. DOI: 10.1007/s40520-015-0333-4

[5] Kovacs CS. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinol Metab Clin North Am. 2011;40(4):795–826. DOI: 10.1016/j.ecl.2011.08.002

[6] Kovacs C.S. Calcium and bone metabolism disorders during pregnancy and lactation//Endocrinol. Metab. Clin. North Am. 2011. Vol. 40. No. 4. P. 795–826. DOI: 10.1016/j.ecl.2011.08.002

[7] Carnevale V, Manfredi G, Romagnoli E, et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage? Clin Endocrinol (Oxf). 2004;60(1):81–86. DOI: 10.1111/j.1365-2265.2004.01946.x

[8] Carnevale V., Manfredi G., Romagnoli E. et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?//Clin. Endocrinol. (Oxf). 2004. Vol. 60. No. 1. P. 81–86. DOI: 10.1111/j.1365-2265.2004.01946.x

[9] Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005;135(2):332–337. DOI: 10.1093/jn/135.2.332

[10] Hanley D.A., Davison K.S. Vitamin D insufficiency in North America//J. Nutr. 2005. Vol. 135. No. 2. P. 332–337. DOI: 10.1093/jn/135.2.332

[11] Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(6 Suppl):1706S–9S. DOI: 10.1093/ajcn/80.6.1706S

[12] Heaney R.P. Functional indices of vitamin D status and ramifications of vitamin D deficiency//Am. J. Clin. Nutr. 2004. Vol. 80. No. 6. (Suppl.). P. 1706S–9S. DOI: 10.1093/ajcn/80.6.1706S

[13] Woodrow JP. Calcitonin modulates skeletal mineral loss during lactation through interactions in mammary tissue and directly though osteoclasts in bone. 2009. [cited 2021 Apr 13]. Available from: https://research.library.mun.ca/8680/1/Woodrow_JanineP.pdf

[14] Woodrow J.P. Calcitonin modulates skeletal mineral loss during lactation through interactions in mammary tissue and directly though osteoclasts in bone. 2009. [дата обращения 13.04.2021.]. Доступ по ссылке: https://research.library.mun.ca/8680/1/Woodrow_JanineP.pdf

[15] Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362–371. Corrected and republished from: Am J Clin Nutr. 2004;79(5):890. DOI: 10.1093/ajcn/79.3.362

[16] Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis//Am. J. Clin. Nutr. 2004. Vol. 79. No. 3. P. 362–371. Corrected and republished from: Am. J. Clin. Nutr. 2004. Vol. 79. No. 5. P. 890. DOI: 10.1093/ajcn/79.3.362

[17] Novikova TV, Zazerskaya IE, Kuznetsova LV, Bart VA. Vitamin D deficiency as a factor in reducing bone mineral density after childbirth. Journal of obstetrics and women’s diseases. 2018;67(6):60–68. (In Russ.). DOI: 10.17816/JOWD67660-68

[18] Новикова Т.В., Зазерская И.Е., Кузнецова Л.В., Барт В.А. Дефицит витамина D как фактор снижения минеральной плотности костной ткани после родов//Журнал акушерства и женских болезней. 2018. Т. 67. № 6. C. 60–68. DOI: 10.17816/JOWD67660-68

[19] Sahin Ersoy G, Giray B, Subas S, et al. Interpregnancy interval as a risk factor for postmenopausal osteoporosis. Maturitas. 2015;82(2):236–240. DOI: 10.1016/j.maturitas.2015.07.014

[20] Sahin Ersoy G., Giray B., Subas S. et al. Interpregnancy interval as a risk factor for postmenopausal osteoporosis//Maturitas. 2015. Vol. 82. No. 2. P. 236–240. DOI: 10.1016/j.maturitas.2015.07.014

[21] Salari P, Abdollahi M. The influence of pregnancy and lactation on maternal bone health: a systematic review. J Family Reprod Health. 2014;8(4):135–148.

[22] Salari P., Abdollahi M. The influence of pregnancy and lactation on maternal bone health: a systematic review//J. Family. Reprod. Health. 2014. Vol. 8. No. 4. P. 135–148.

[23] Novikova TV, Zazerskaya IE, Kuznetsova LV, et al. Vitamin D and mineral metabolism after childbirth with the use of preventive doses of cholecalciferol. Journal of obstetrics and women’s diseases. 2019;68(5):45–53. (In Russ.). DOI: 10.17816/JOWD68545-53

[24] Новикова Т.В., Зазерская И.Е., Кузнецова Л.В. и др. Витамин D и показатели минерального обмена после родов при применении профилактических доз холекальциферола//Журнал акушерства и женских болезней. 2019. Т. 68. № 5. C. 45–53. DOI: 10.17816/JOWD68545-53

[25] Novikova TV, Kuznetsova LV, Yakovleva NYu, Zazerskaya IE. Factors influencing bone mineral density in postpartum women. Osteoporosis and Bone Diseases. 2018;21(1):10–16. (In Russ.). DOI: 10.14341/osteo9653

[26] Новикова Т.В., Кузнецова Л.В., Яковлева Н.Ю., Зазерская И.Е. Факторы, ассоциированные со снижением МПК в послеродовом периоде//Остеопороз и остеопатии. 2018. Т. 21. № 1. С. 1016. DOI: 10.14341/osteo9653

[27] Vasileva EN, Denisova TG, Gunin AG, Trishina EN. Vitamin D deficiency during pregnancy and breastfeeding. Sovremennye problemy nauki i obrazovaniya. 2015;(4):470. (In Russ.)

[28] Васильева Э.Н., Денисова Т.Г., Гунин А.Г., Тришина Е.Н. Дефицит витамина D во время беременности и грудного вскармливания//Современные проблемы науки и образования. 2015. № 4. С. 470

[29] Osteoporoz. Klinicheskie rekomendacii Ministerstva Zdravoohranenija Rossijskoj Federacii [cited 2021 Apr 13]. Available from: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_osteopor_12.12.16.pdf

[30] Остеопороз. Клинические рекомендации Министерства здравоохранения Российской Федерации, 2016. [дата обращения 13.04.2021.]. Доступ по ссылке: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/rec_osteopor_12.12.16.pdf

[31] Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–787. DOI: 10.1007/s001980200108

[32] Van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis//Osteoporos Int. 2002. Vol. 13. No. 10. P. 777–787. DOI: 10.1007/s001980200108

[33] Seredavkina NV, Reshetnyak TM. Osteoporosis in systemic lupus erythematosus. Modern Rheumatology Journal. 2009;3(4):59–66. (In Russ.). DOI: 10.14412/1996-7012-2009-575

[34] Середавкина Н.В., Решетняк Т.М. Остеопороз при системной красной волчанке//Современная ревматология. 2009. Т. 3. № 4. С. 59–66. DOI: 10.14412/1996-7012-2009-575

[35] Zazerskaya IE, Novikova TV, Shelepova ES, et al. Distribution of bone mineral density in parts of skeleton in puerperants with different levels of vitamin D. Giornale Italiano di Ostetricia e Ginecologia. 2014;36(1):308–312.

[36] Zazerskaya I.E., Novikova T.V., Shelepova E.S. et al. Distribution of bone mineral density in parts of skeleton in puerperants with different levels of vitamin D//Giornale Italiano di Ostetricia e Ginecologia. 2014. Vol. 36. № 1. P. 308–312.

[37] Rebrov VG, Gromova OA. Vitaminy, makro- i mikroelementy. Moscow: GEOTAR-Med; 2008. (In Russ.)

[38] Ребров В.Г., Громова О.А. Витамины, макро-и микроэлементы. Москва: ГЭОТАР-Медиа, 2008.

[39] Limanova OA, Torshin IIu, Sardarian IS, еt al Obespechennost’ mikronutrientami i zhenskoe zdorov’e: intellektual’nyi analiz kliniko-epidemiologiches-kikh dannykh. Vopr. ginekologii, akusherstva iperinatologii. 2014;(2):5–15. (In Russ.)

[40] Лиманова О.А., Торшин И.Ю., Сардарян И.С. и др. Обеспеченность микронутриентами и женское здоровье: интеллектуальный анализ клинико-эпидемиологических данных//Вопросы гинекологии, акушерства и перинатологии. 2014. № 2. С. 5–15.

[41] Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014;71(23):2029–2036. DOI: 10.2146/ajhp140041

[42] Green S.B., Pappas A.L. Effects of maternal bisphosphonate use on fetal and neonatal outcomes//Am. J. Health Syst. Pharm. 2014. Vol. 71. No. 23. P. 2029–2036. DOI: 10.2146/ajhp140041

[43] Sokal A, Elefant E, Leturcq T, et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int. 2019;30(1):221–229. DOI: 10.1007/s00198-018-4672-9

[44] Sokal A., Elefant E., Leturcq T. et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study//Osteoporos Int. 2019. Vol. 30. No. 1. P. 221–229. DOI: 10.1007/s00198-018-4672-9

[45] Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10(4):280–291. DOI: 10.14310/horm.2002.1319

[46] Stathopoulos I.P., Liakou C.G., Katsalira A. et al. The use of bisphosphonates in women prior to or during pregnancy and lactation//Hormones (Athens). 2011. Vol. 10. No. 4. P. 280–291. DOI: 10.14310/horm.2002.1319

[47] Nzeusseu Toukap A, Depresseux G, Devogelaer JP, Houssiau FA. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients. Lupus. 2005;14(7):517–520. DOI: 10.1191/0961203305lu2149oa

[48] Nzeusseu Toukap A., Depresseux G., Devogelaer J.P., Houssiau F.A. Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients//Lupus. 2005. Vol. 14. No. 7. P. 517–520. DOI: 10.1191/0961203305lu2149oa

[49] Hardcastle SA. Pregnancy and lactation associated osteoporosis. Calcif Tissue Int. 2021. DOI: 10.1007/s00223-021-00815-6

[50] Hardcastle S.A. Pregnancy and lactation associated osteoporosis//Calcif. Tissue Int. 2021. DOI: 10.1007/s00223-021-00815-6.

[51] Deficit vitamina D u vzroslyh. Klinicheskie rekomendacii Ministerstva Zdravoohranenija Rossijskoj Federacii. 2016. [cited 2021 Apr 13]. Available from: https://rae-org.ru/system/files/documents/pdf/kr342_deficit_vitamina_d_u_vzroslyh.pdf.

RIGHTS & PERMISSIONS

Eсо-Vector